Jaundiced Sclera: What It Means and How to Manage It

What is Jaundiced Sclera?

Jaundiced sclera (also called “yellow eyes”) describes a yellow‑tinged appearance of the white part of the eye (the sclera). The discoloration occurs when excess bilirubin – a yellow pigment produced by the breakdown of red blood cells – accumulates in the bloodstream and deposits in tissues with a high blood supply, such as the sclera.

Bilirubin is normally processed by the liver, converted into a water‑soluble form, and excreted in bile. When this pathway is disrupted, bilirubin levels rise (hyperbilirubinemia) and the eyes may turn yellow before the skin does, making scleral icterus one of the earliest visual cues of liver or blood‑related problems.

Because the sclera is thin and richly vascular, even modest bilirubin elevations (≈2–3 mg/dL) can cause noticeable yellowing, whereas the skin often requires higher levels. Recognizing jaundiced sclera can prompt earlier medical evaluation and treatment.

Common Causes

Many diseases and conditions can lead to elevated bilirubin and consequently jaundiced sclera. Below are 10 of the most frequently encountered causes:

• Acute viral hepatitis (A, B, C, D, E) – Inflammation damages liver cells, impairing bilirubin processing.
• Alcoholic liver disease – Chronic alcohol use leads to fatty liver, hepatitis, and cirrhosis.
• Non‑alcoholic fatty liver disease (NAFLD) / Non‑alcoholic steatohepatitis (NASH) – Metabolic syndrome‑related fat accumulation in the liver.
• Bile duct obstruction – Gallstones, cholangiocarcinoma, or strictures block bile flow, causing bilirubin buildup.
• Hemolytic anemia – Accelerated destruction of red blood cells releases excess heme, increasing bilirubin production.
• Genetic disorders – e.g., Gilbert’s syndrome, Crigler‑Najjar syndrome, and Dubin‑Johnson syndrome affect bilirubin metabolism.
• Drug‑induced liver injury – Acetaminophen overdose, certain antibiotics, and antiretrovirals can damage hepatocytes.
• Sepsis and severe infections – Systemic inflammation can impair liver function and cause cholestasis.
• Pancreatic cancer or pancreatic head tumors – Can compress the common bile duct, leading to obstructive jaundice.
• Pregnancy‑related cholestasis – Hormonal changes reduce bile flow, especially in the third trimester.

Associated Symptoms

Jaundiced sclera is rarely an isolated finding. Patients often experience other signs that point toward the underlying cause:

• Yellowing of the skin and mucous membranes (icterus)
• Dark urine – bilirubin excreted by the kidneys.
• Pale, clay‑colored stools – lack of bile pigments.
• Pruritus (itching) – due to accumulation of bile salts in skin.
• Abdominal pain or fullness – especially in the right upper quadrant.
• Fatigue, malaise, or loss of appetite
• Fever or chills – suggest infection or cholangitis.
• Jaundice‑related night blindness – rare, from vitamin A deficiency in chronic liver disease.
• Easy bruising or bleeding – impaired production of clotting factors.
• Weight loss or loss of appetite – common in malignancy or chronic liver disease.

When to See a Doctor

While occasional mild yellowing can be benign (e.g., Gilbert’s syndrome), you should schedule a medical evaluation promptly if you notice any of the following:

• Jaundiced sclera persisting longer than a few days.
• Accompanying dark urine, pale stools, or intense itching.
• Fever, chills, or severe abdominal pain.
• Sudden onset of confusion, drowsiness, or difficulty concentrating (possible hepatic encephalopathy).
• Unexplained weight loss, night sweats, or a palpable abdominal mass.
• History of liver disease, heavy alcohol use, recent travel to areas with hepatitis outbreaks, or recent use of potentially hepatotoxic drugs.

Early assessment can prevent progression to liver failure or identify treatable conditions such as gallstone obstruction.

Diagnosis

Evaluation of jaundiced sclera follows a stepwise approach to determine bilirubin levels, liver function, and the underlying cause.

1. Clinical Examination

• Inspection of sclera, skin, and mucous membranes for yellowing.
• Abdominal exam for hepatomegaly, tenderness, or gallbladder enlargement.
• Neurologic assessment for asterixis or altered mental status.

2. Laboratory Tests

• Serum bilirubin – total & direct (conjugated) levels.
• Liver panel – ALT, AST, alkaline phosphatase, GGT, albumin.
• Coagulation profile – PT/INR to gauge liver synthetic function.
• Complete blood count – evaluates for hemolysis or infection.
• Hemolysis work‑up – haptoglobin, LDH, reticulocyte count, peripheral smear.
• Viral hepatitis serologies – Hepatitis A, B, C, D, E antibodies/antigens.
• Autoimmune markers – ANA, SMA, LKM-1 if autoimmune hepatitis is suspected.
• Metabolic panels – fasting glucose, lipid profile (relevant for NAFLD).

3. Imaging Studies

• Ultrasound – first‑line to assess liver texture, gallstones, and biliary dilation.
• CT or MRI – detailed evaluation for tumors, pancreatobiliary obstruction, or vascular lesions.
• MRCP (Magnetic Resonance Cholangiopancreatography) – non‑invasive view of the biliary tree.

4. Specialized Tests (if indicated)

• Endoscopic retrograde cholangiopancreatography (ERCP) – for therapeutic stone removal or stenting.
• Liver biopsy – definitive diagnosis for certain chronic liver diseases.
• Genetic testing – for hereditary bilirubin metabolism disorders.

Treatment Options

Therapy is directed at the root cause; supportive care helps relieve symptoms while the underlying disease is managed.

1. Addressing the Underlying Condition

• Viral hepatitis – antiviral agents (e.g., tenofovir for HBV, direct‑acting antivirals for HCV) per CDC/WHO guidelines.
• Bile duct obstruction – endoscopic stone extraction, stenting, or surgical decompression.
• Alcoholic liver disease – complete abstinence, nutritional support, and possibly corticosteroids for severe alcoholic hepatitis.
• NAFLD/NASH – weight loss (7–10 % body weight), exercise, control of diabetes and hyperlipidemia.
• Hemolytic anemia – treat the trigger (e.g., stop offending drug, manage autoimmune disease, transfusions if needed).
• Drug‑induced injury – stop the offending medication; N‑acetylcysteine for acetaminophen toxicity.
• Genetic syndromes – often benign; occasional phototherapy for neonatal jaundice in Crigler‑Najjar type II.

2. Symptomatic & Supportive Care

• Hydration – adequate oral fluids help bilirubin excretion.
• Pruritus relief – cholestyramine, antihistamines, or rifampin under physician supervision.
• Nutritional support – high‑protein, low‑fat diet; supplement fat‑soluble vitamins (A, D, E, K) if cholestasis is chronic.
• Phototherapy – reserved for severe neonatal hyperbilirubinemia.

3. Monitoring

Regular follow‑up labs (bilirubin, liver enzymes, INR) are essential to track response and detect complications such as progression to cirrhosis or hepatic decompensation.

Prevention Tips

While some causes (genetics) cannot be altered, many risk factors for jaundiced sclera are modifiable:

• Vaccinate against hepatitis A and B.
• Limit alcohol intake – no more than 2 drinks/day for men, 1 for women.
• Maintain a healthy weight – balanced diet, regular exercise to lower NAFLD risk.
• Practice safe sex and avoid needle sharing – reduces hepatitis C transmission.
• Use medications responsibly – follow dosing guidelines, avoid unnecessary over‑the‑counter combos.
• Promptly treat infections – especially gallbladder disease or cholangitis.
• Regular health screenings – liver function tests for high‑risk individuals (e.g., diabetics, chronic alcohol users).
• Stay hydrated – adequate fluid intake supports liver detoxification.

Emergency Warning Signs

References (selected):

• Mayo Clinic. Jaundice. https://www.mayoclinic.org/diseases-conditions/jaundice/
• Centers for Disease Control and Prevention. Hepatitis A, B, C Frequently Asked Questions. https://www.cdc.gov/hepatitis/
• National Institute of Diabetes and Digestive and Kidney Diseases. Non‑alcoholic Fatty Liver Disease. https://www.niddk.nih.gov/health-information/liver-disease/nafld
• World Health Organization. Guidelines for the Prevention and Treatment of Hepatitis. https://www.who.int/publications/i/item/9789240017709
• Cleveland Clinic. Hemolytic Anemia. https://my.clevelandclinic.org/health/diseases/17203-hemolytic-anemia
• American College of Gastroenterology. Guidelines for the Management of Gallstone Disease. 2023.